The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Tyrosine kinase – Role and significance in Cancer
Open accessAbstract
Tyrosine kinases are important mediators of the signaling cascade, determining key roles in diverse biological processes like growth, differentiation, metabolism and apoptosis in response to external and internal stimuli. Recent advances have implicated the role of tyrosine kinases in the pathophysiology of cancer. Though their activity is tightly regulated in normal cells, they may acquire transforming functions due to mutation(s), overexpression and autocrine paracrine stimulation, leading to malignancy. Constitutive oncogenic activation in cancer cells can be blocked by selective tyrosine kinase inhibitors and thus considered as a promising approach for innovative genome based therapeutics. The modes of oncogenic activation and the different approaches for tyrosine kinase inhibition, like small molecule inhibitors, monoclonal antibodies, heat shock proteins, immunoconjugates, antisense and peptide drugs are reviewed in light of the important molecules. As angiogenesis is a major event in cancer growth and proliferation, tyrosine kinase inhibitors as a target for anti-angiogenesis can be aptly applied as a new mode of cancer therapy. The review concludes with a discussion on the application of modern techniques and knowledge of the kinome as means to gear up the tyrosine kinase drug discovery process.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Genome maintenance mechanisms for preventing cancer
Hoeijmakers, J. H. J. (2001) · Nature · doi:10.1038/35077232 · Cited by 3,939
Cell Signaling by Receptor Tyrosine Kinases
Schlessinger, J. (2000) · Cell · doi:10.1016/s0092-8674(00)00114-8 · Cited by 3,774
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
Molecular chaperones in cellular protein folding
Hartl, F. U. (1996) · Nature · doi:10.1038/381571a0 · Cited by 3,568
Specificity and mechanism of action of some commonly used protein kinase inhibitors
DAVIES, S. P., REDDY, H., CAIVANO, M., & COHEN, P. (2000) · Biochemical Journal · doi:10.1042/bj3510095 · Cited by 3,132
Protein kinases and phosphatases: The Yin and Yang of protein phosphorylation and signaling
Hunter, T. (1995) · Cell · doi:10.1016/0092-8674(95)90405-0 · Cited by 2,950
Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J.-Y., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.038 · Cited by 2,874
The Hsp70 and Hsp60 Chaperone Machines
Bukau, B., & Horwich, A. L. (1998) · Cell · doi:10.1016/s0092-8674(00)80928-9 · Cited by 2,815
A synthetic inhibitor of the mitogen-activated protein kinase cascade.
Dudley, D. T., Pang, L., Decker, S. J., Bridges, A. J., & Saltiel, A. R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.17.7686 · Cited by 2,679
Hunter, T. (2000) · Cell · doi:10.1016/s0092-8674(00)81688-8 · Cited by 2,586
Hunter, T., & Cooper, J. A. (1985) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.54.070185.004341 · Cited by 2,107
Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study
Chan, J. M., Stampfer, M. J., Giovannucci, E., Gann, P. H., Ma, J., Wilkinson, P., Hennekens, C. H., & Pollak, M. (1998) · Science · doi:10.1126/science.279.5350.563 · Cited by 1,996
Daley, G. Q., Van Etten, R. A., & Baltimore, D. (1990) · Science · doi:10.1126/science.2406902 · Cited by 1,756
Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
Boehm, T., Folkman, J., Browder, T., & O'Reilly, M. S. (1997) · Nature · doi:10.1038/37126 · Cited by 1,683
Dimerization of cell surface receptors in signal transduction
Heldin, C.-H. (1995) · Cell · doi:10.1016/0092-8674(95)90404-2 · Cited by 1,634
Golub, T. R., Barker, G. F., Lovett, M., & Gilliland, D. G. (1994) · Cell · doi:10.1016/0092-8674(94)90322-0 · Cited by 1,155
Fong, T. A. T., Shawver, L. K., Sun, L., Tang, C., App, H., Powell, T., Kim, Y. H., Schreck, R., Wang, X., Risau, W., et al. (1999) · PubMed · Cited by 1,026
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR
Neshat, M. S., Mellinghoff, I. K., Tran, C., Stiles, B., Thomas, G., Petersen, R., Frost, P., Gibbons, J. J., Wu, H., & Sawyers, C. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171076798 · Cited by 969
A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity.
Nishikawa, R., Ji, X. D., Harmon, R. C., Lazar, C. S., Gill, G. N., Cavenee, W. K., & Huang, H. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.16.7727 · Cited by 936
Wong, A. J., Bigner, S. H., Bigner, D. D., Kinzler, K. W., Hamilton, S. R., & Vogelstein, B. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.19.6899 · Cited by 849
Hermanson, M., Funa, N. S., Hartman, M., Claesson, L., Heldin, C., Westermark, B., & Nistér, M. (1992) · PubMed · Cited by 705
Herceptin acts as an anti-angiogenic cocktail
Izumi, Y., Xu, L., di Tomaso, E., Fukumura, D., & Jain, R. K. (2002) · Nature · doi:10.1038/416279b · Cited by 623
Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors
Gazit, A., Yaish, P., Gilon, C., & Levitzki, A. (1989) · Journal of Medicinal Chemistry · doi:10.1021/jm00130a020 · Cited by 600
Blocking of EGF-Dependent Cell Proliferation by EGF Receptor Kinase Inhibitors
Yaish, P., Gazit, A., Gilon, C., & Levitzki, A. (1988) · Science · doi:10.1126/science.3263702 · Cited by 587
The molecular biology of cancer
Bertram, J. S. (2000) · Molecular Aspects of Medicine · doi:10.1016/s0098-2997(00)00007-8 · Cited by 585
Rusch, V. W., Baselga, J. M., Cordon‐Cardo, C., Orazem, J. P., Zaman, M., Hoda, S. A., McIntosh, J., Kurie, J. M., & Dmitrovsky, E. (1993) · PubMed · Cited by 482
Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain
Mohammadi, M. (1998) · The EMBO Journal · doi:10.1093/emboj/17.20.5896 · Cited by 482
Weinberg, R. A. (1996) · Scientific American · doi:10.1038/scientificamerican0996-62 · Cited by 465
Epidermal growth factor stimulates phosphorylation in membrane preparations in vitro
CARPENTER, G., KING, L., & COHEN, S. (1978) · Nature · doi:10.1038/276409a0 · Cited by 454
Shiota, M., Nakamura, S., Ichinohasama, R., Abe, M., Akagi, T., Takeshita, M., Mori, N., Fujimoto, J., Miyauchi, J., & Mikata, A. (1995) · Blood · doi:10.1182/blood.v86.5.1954.bloodjournal8651954 · Cited by 380
A cancer therapy resistant to resistance
Kerbel, R. S. (1997) · Nature · doi:10.1038/36978 · Cited by 369
Protein kinases as targets for anticancer agents: from inhibitors to useful drugs
Fabbro, D., Ruetz, S., Buchdunger, E., Cowan-Jacob, S. W., Fendrich, G., Liebetanz, J., Mestan, J., O'Reilly, T., Traxler, P., Chaudhuri, B., et al. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00179-1 · Cited by 335
Drevs, J., Hofmann, I., Hugenschmidt, H., Wittig, C., Madjar, H., Müller, M., Wood, J. M., Martiny‐Baron, G., Unger, C., & Marmé, D. (2000) · PubMed · Cited by 308
Protein tyrosine kinases and cancer
Kolibaba, K. S., & Druker, B. J. (1997) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(97)00022-x · Cited by 291
Receptor tyrosine kinases as targets for anticancer drugs
Zwick, E., Bange, J., & Ullrich, A. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(01)02217-1 · Cited by 252
Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene
Goga, A., McLaughlin, J., Afar, D. E. H., Saffran, D. C., & Witte, O. N. (1995) · Cell · doi:10.1016/0092-8674(95)90277-5 · Cited by 248
STI571 (Gleevec™) as a paradigm for cancer therapy
Druker, B. J. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02305-5 · Cited by 245
Signal perception and transduction: the role of protein kinases
Schenk, P. W., & Snaar-Jagalska, B. E. (1999) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/s0167-4889(98)00178-5 · Cited by 231
Andrews, D. W., Resnicoff, M., Flanders, A. E., Kenyon, L., Curtis, M., Merli, G., Baserga, R., Iliakis, G., & Aiken, R. D. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2189 · Cited by 222
Immunotoxins in cancer therapy
Kreitman, R. J. (1999) · Current Opinion in Immunology · doi:10.1016/s0952-7915(99)00005-9 · Cited by 215
Tyrosine kinase receptors as attractive targets of cancer therapy
Bennasroune, A., Gardin, A., Aunis, D., Crémel, G., & Hubert, P. (2004) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2003.08.004 · Cited by 197
The development and therapeutic potential of protein kinase inhibitors
Cohen, P. (1999) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(99)80067-2 · Cited by 182
Resnik, J. L., Reichart, D. B., Huey, K., Webster, N. J. G., & Seely, B. L. (1998) · PubMed · Cited by 173
Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion
Grossbard, M., Freedman, A. S., Ritz, J., Coral, F., Goldmacher, V. S., Eliseo, L. J., Spector, N., Dear, K. B. G., Lambert, J., & Blättler, W. A. (1992) · Blood · doi:10.1182/blood.v79.3.576.576 · Cited by 171
Inhibition of Hsp90: a new strategy for inhibiting protein kinases
Sreedhar, A. S., Sőti, C., & Csermely, P. (2003) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2003.11.027 · Cited by 148
Münster, P. N., Srethapakdi, M., Moasser, M. M., & Rosen, N. X. (2001) · PubMed · Cited by 145
Activated neu Induces Rapid Tumor Progression
Guy, C. T., Cardiff, R. D., & Muller, W. J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.13.7673 · Cited by 145
Rational therapeutic intervention in cancer: kinases as drug targets
Sawyers, C. L. (2002) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(01)00273-8 · Cited by 129
Tyrosine kinases as targets for cancer therapy
Levitzki, A. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)80598-6 · Cited by 107
Bcr-Abl inhibition as a modality of CML therapeutics
Buchdunger, E., Matter, A., & Druker, B. J. (2001) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(01)00022-1 · Cited by 102
Smith, K., Fennelly, J. A., Neal, D. E., Hall, R., & Harris, A. L. (1989) · PubMed · Cited by 101
Fischer, O. M., Streit, S., Hart, S., & Ullrich, A. (2003) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(03)00082-6 · Cited by 95
Disabling Receptor Ensembles with Rationally Designed Interface Peptidomimetics
Berezov, A., Chen, J., Liu, Q., Zhang, H., Greene, M. I., & Murali, R. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202880200 · Cited by 93
Kedar, D. J., Baker, C. H., Killion, J. J., Dinney, C. P., & Fidler, I. J. (2002) · PubMed · Cited by 92
Reeve, J. G., Morgan, J., Schwander, J., & Bleehen, N. M. (1994) · Lung Cancer · doi:10.1016/0169-5002(94)90316-6 · Cited by 87
Protein tyrosine kinase inhibitors: new treatment modalities?
Fabbro, D. (2002) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(02)00179-0 · Cited by 86
Kreitman, R. J., Chaudhary, V. K., Waldmann, T. A., Willingham, M. C., FitzGerald, D. J., & Pastan, I. H. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.21.8291 · Cited by 78
Protein tyrosine kinases: autoregulation and small-molecule inhibition
Hubbard, S. R. (2002) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(02)00383-4 · Cited by 77
Progress in immunoconjugate cancer therapeutics
Payne, G. M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00057-6 · Cited by 76
Translating basic cancer research into new cancer therapeutics
Workman, P., & Kaye, S. B. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02319-5 · Cited by 74
A decade of tyrosine kinases: from gene discovery to therapeutics
Craven, R. J., Lightfoot, H. M., & Cance, W. G. (2003) · Surgical Oncology · doi:10.1016/s0960-7404(03)00004-5 · Cited by 60
Park, J., Yeh, M. W., Wong, M. G., Lobo, M., Hyun, W. C., Duh, Q., & Clark, O. H. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020340 · Cited by 58
The fabric of cancer cell biology—Weaving together the strands
Klausner, R. D. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00020-x · Cited by 57
Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J.-Y., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02499 · Cited by 53
Targeted therapies in myeloid leukemia
John, A. M., Thomas, N. S. B., Mufti, G. J., & Padua, R. A. (2004) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2003.11.006 · Cited by 52
The TEL gene and human leukemia
Golub, T. R., McLean, T. W., Stegmaier, K., Carroll, M. C., Tomasson, M. H., & Gilliland, D. G. (1996) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(96)00015-7 · Cited by 50
Scoring a bull's-eye against cancer genome targets
Workman, P. (2001) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(01)00060-1 · Cited by 49
Lewis, L. D., Beelen, A. P., Cole, B. F., Wallace, P. K., Fisher, J. L., Waugh, M., Kaufman, P. A., & Ernstoff, M. S. (2002) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-002-0424-8 · Cited by 16
Cited by
Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer
Patra, C. R., Bhattacharya, R., Mukhopadhyay, D., & Mukherjee, P. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.11.007 · Cited by 458
Thiazole-containing compounds as therapeutic targets for cancer therapy
Sharma, P. C., Bansal, K. K., Sharma, A., Sharma, D., & Deep, A. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.112016 · Cited by 382
Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells
Garg, P., Malhotra, J., Kulkarni, P., Horne, D., Salgia, R., & Singhal, S. S. (2024) · Cancers · doi:10.3390/cancers16132478 · Cited by 339
Activating alleles of JAK3 in acute megakaryoblastic leukemia
Walters, D. K., Mercher, T., Gu, T.-L., O'Hare, T., Tyner, J. W., Loriaux, M., Goss, V. L., Lee, K. A., Eide, C. A., Wong, M. J., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.06.002 · Cited by 317
Targeting tumour microenvironment by tyrosine kinase inhibitor
Tan, H.-Y., Wang, N., Lam, W., Guo, W., Feng, Y., & Cheng, Y.-C. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0800-6 · Cited by 107
Metadata
- Authors
- Paul, M. K., & Mukhopadhyay, A. K.
- Venue
- International Journal of Medical Sciences
- Publisher
- Ivyspring International Publisher
- Published
- 2004
- Volume
- 1
- Issue
- 2
- Pages
- 101-115
- ISSN
- 1449-1907 (ISSN-L)
- OpenAlex
- W2160605524
- Cited by
- 624
- References
- 72
- FWCI
- 3.17
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.